PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
 
Oral Oncol. 2008 February; 44(2-2): 156–161.
PMCID: PMC2691586
EMSID: UKMS5077

Expression of novel p53 isoforms in oral lichen planus

Summary

Oral lichen planus (OLP) is a chronic inflammatory disease of unknown origin, showing little spontaneous regression. WHO classifies OLP as a premalignant condition, however, the underlying mechanisms initiating development of cancer in OLP lesions are not understood. The p53 tumour suppressor plays an important role in many tumours, and an increased expression of p53 protein has been seen in OLP lesions. Recently it was shown that the human TP53 gene encodes at least nine different isoforms. Another member of the p53 family, p63, comprises six different isoforms and plays a crucial role in the formation of oral mucosa, salivary glands, teeth and skin. It has also been suggested that p63 is involved in development of squamous cell carcinoma of the head and neck (SCCHN). In contrast to p53, a decreased expression of p63 protein has been seen in OLP lesions. In this study, we mapped the expression of five novel p53 isoforms at RNA and protein levels in OLP and matched normal controls. In the same samples we also measured levels of p63 isoforms using quantitative RT–PCR. Results showed p53 to be expressed in all OLP lesions and normal tissues. The p53β and Δ133p53 isoforms were expressed in the majority of samples whereas the remaining three novel isoforms analysed were expressed in only a few samples. Levels of p63 isoforms were lower in OLP lesions compared with normal tissue, however, changes were not statistically significant.

Keywords: p53, p63, Isoforms, OLP

Introduction

Oral lichen planus (OLP) is a chronic inflammatory disease of skin and mucosa affecting approximately 1–2% of the adult population. The disease occurs more frequently in women than in men (1.4:1) and is more common in middle aged and elderly than in young people.1 In contrast to lichen of the skin, OLP seems to have a chronic cause with low tendency to spontaneous regression and high resistance to topical treatment.2 Despite numerous studies the origin remains unknown. However, an autoimmune cause has been suggested3 and we have recently demonstrated occurrence of auto antibodies against p63 and p73 in sera from patients diagnosed with OLP.4

OLP lesions have a higher cell turnover than normal tissue5 and WHO classifies OLP as a premalignant condition making “oral mucosa more sensitive to exogenous carcinogens and thus to develop oral carcinoma”.6 Malignant transformation to squamous cell carcinoma has been seen in 2–3% of OLP patients. Females with OLP run a 50% higher risk of developing squamous cell carcinoma of the head and neck (SCCHN) compared to a control group.6 The underlying mechanisms initiating development into SCCHN have not been clarified, however, an association between chronic inflammation and a variety of cancers is known.7–9

Approximately two decades ago the p53 tumour suppressor was discovered. Activation of p53 after DNA damage or oncogenic signalling is an important protective mechanism enabling DNA repair, induction of cell cycle arrest or apoptosis. Mutation within the human TP53 gene is found in approximately half of all human tumours studied and a high prevalence of TP53 mutations has been seen in patients diagnosed with OLP, particularly females.10 We and other investigators have previously shown an increased expression of p53 protein in OLP lesions compared with normal tissue.10–18

Recently it was shown that human p53 encodes at least nine different isoforms through alternative splicing, alternative initiation sites for translation and the use of an internal promoter: p53, p53β, p53γ, Δ133p53, Δ133p53β, Δ133p53γ, Δ40p53, Δ40p53β and Δ40p53γ.19 In the first study of these novel p53 isoforms in SCCHN it was shown that p53 variant mRNAs were expressed in both normal oral epithelium and SCCHN. The most common of these isoforms being p53β, which was detected in the majority of samples. Of the other isoforms studied all but Δp53 could be detected in at least some samples from tumour and normal epithelium.20

The p53 relative p63 is encoded by a gene located on chromosome 3q27–29. In humans this gene encodes six different isoforms: TAp63α, TAp63β, TAp63γ, ΔNp63α, ΔNp63β and ΔNp63γ.21,22 p63 is essential for development of ectodermal structures, and p63 −/− mice lack oral mucosa, skin, teeth, hair follicles, salivary and mammary glands.23,24 The exact function of each individual isoform is, however, not clear. It is known that each of the p63 proteins have different characteristics and functions, where some resemble its relative the tumour suppressor protein p53, while others have the opposite function.25 We have previously shown a decreased expression of the different p63 proteins in OLP lesions compared with normal oral mucosa.18 Concerning RNA levels of the different isoforms, no data is as of today available.

The aim of the present study was to clarify if the observed increased expression of p53 protein seen in OLP lesions represents a mixture of the different novel p53 isoforms or the original p53 isoform only. Furthermore we wanted to see in the same samples, if there was any correlation between RNA levels of the different p63 isoforms, and the decrease in protein expression that we have previously seen in these lesions. In order to judge whether OLP in this aspect resembles normal or tumour tissue, normal matched control tissue was analysed in parallel, and results compared with data from analysis of SCCHN.

Materials and methods

Patients and specimens

Two 4 mm punch biopsies were, after informed consent, taken from the buccal mucosa on 20 consecutive patients with OLP referred to the specialist clinic at the department of Odontology, Umeå University. All patients were clinically and histologically diagnosed with oral lichen planus. Fourteen were females with a mean age of 63.5 (range 42–78) and six were males with a mean age of 59.5 (range 48–75). Biopsies were also collected from twenty sex and age matched healthy controls. All samples were immediately frozen and stored at −80 °C. Permission for the study hade been granted by the Ethical Committee at Umeå University (dnr 05–010 M).

RNA extraction

One of the frozen biopsies was cut into pieces in a Petri dish placed on dry ice and transferred into a 1.5 ml tube containing 250 μl TRIzol reagent (Invitrogen). Samples were homogenized using a pellet mixer (MARCK Eurolab), a further 750 μl of TRIzol added and samples incubated at room temperature for 5 min. Mixtures were then centrifuged for 15 min at 13,000 rpm at 4 °C. The upper liquid phase was moved to a new tube, diluted with an equal amount of isopropyl alcohol, incubated for 10 min and again centrifuged for 10 min at 4 °C. The upper layer was carefully removed and pellets washed in 70% ethanol before drying and dissolved in DePc-H2O by pipetting 10–20 times, heated to 60 ° C for 10 min and pipetted another 10–20 times. Extracted RNA was then kept at −80 °C until use.

cDNA synthesis and RT–PCR for analysis of p53 isoforms

cDNA was synthesized using a Cloned AMW First-Stand cDNA Synthesis kit (Invitrogen) according to the manufacturers instructions. One microgram of RNA was added into a total reaction volume of 20 μl. The cDNA was amplified in two rounds of PCR (nested PCR) in order to detect the different isoforms of p53. The following p53-specific primer sets were used: for the first PCR-round of p53, p53β, and p53γ: e2.1/RT1. For Δ133p53, Δ133p53β, and Δ133p53γ: i4f1/RT2 were used. For the nested PCR the primers for p53 were: e2/RT2; for p53β: e2/p53b; for p53γ: e2/p53g; for Δ133p53: i4f2/RDNp53; for Δ133p53β: i4f2/p53b, and for Δ133p53γ: i4f2/p53g.

Primer sequences:e2.1(5-GTCACTGCCATGGAGGAGCCGCA-3)e2(5-ATGGAGGAGCCGCAGTCAGAT-3)i4f1(5-CTGAGGTGTAGACGCCAACTCTCTCTAG-3)i4f2(5-GCTAGTGGGTTGCAGGAGGTGCTTACAC-3)RT1(5-GACGCACACCTATTGCAAGCAAGGGTTC-3)RT2(5-AATGTCAGTCTGAGTCAGGCCCTTCTGTC-3)p53b(5-TTTGAAAGCTGGTCTGGTCCTGA-3)p53g(5-TCGTAAGTCAAGTAGCATCTGAAGG-3)RDNp53(5-CTCACGCCCACGGATCTGA-3)

The PCR programme comprised 35 cycles with 94 °C for 30 s, 60 °C for 45 s and 72 °C for 90 s. PCR products were loaded on a 1% agarose gel.19 All samples were done in duplicate and most of them in triplicate, and considered positive when positive in all replicates, or positive/variable when isoforms were detected in at least one PCR run.

Quantitative PCR for analysis of p63 isoforms

Quantitative RT–PCR for analysis of p63 isoforms was performed using a human p63/β-actin multi-parametric kit (Search LC, Heidelberg, Germany) and analysed on a Lightcycler™ from Roche. In brief, cDNA was diluted 12 times and then mixed with the different primer sets to amplify each of the p63 splice variant mRNAs individually and, simultaneously amplify β-actin to serve as an internal control for cDNA integrity and relative cDNA quantity in the different tissue samples. Primers were selected to bridge intronic sequences in order to discriminate between amplification of cDNA and contaminating genomic DNA. Reactions were analysed on the LightcyclerTM with one denaturation cycle, 50 amplification cycles, one melting curve analysis cycle, and, finally, one cooling cycle. Reactions were run in duplicate, and a mean value of the two samples was calculated.26

Statistical analysis

For analysis of p63 mRNA levels in OLP lesions and corresponding clinically normal oral mucosa an independent samples T-test was performed using Computer software SPSS version 12.0.

Protein extraction

From one frozen biopsy protein was extracted using a Micro-dismembrator (B. Braun. Biotech International) for pulverizing the sample. One hundred microliter of lysis buffer containing 0.5% NP-40, 0.5% Na-doc, 0.1% SDS, 150 mM NaCl, 50 mM Tris pH 7.5, 1 mM EDTA, 1 mM NaF and protease inhibitor cocktail (Sigma-Aldrich Chemie, Steinheim, Germany) was added and the pulverized samples homogenized. Protein concentrations were determined using BCA Protein Assay Kit (Pierce, Rockford, IL, USA).

Immunoblot analysis and quantification

Bio-Rad PROTEAN II xi [mid ] XL Vertical Electrophoresis system or vertical mini-gels were used according to the user manual. Thirty microgram of protein was mixed with 2× loading buffer, boiled for 10 min and electrophoresed on 10% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose membranes (Hybond ECL, Amersham Biosciences, Little Chalton, NA, USA) and stained with ponceau red for evaluation of transfer efficiency and loading. Membranes were blocked in 5% milk with 0.4% Tween in 1X PBS, and antibodies diluted in the same blocking solution. Primary antibodies used in this study were DO-1 for detection of p53, p53β, p53γ.27, and DO-12 for detection of p53, p53β, p53γ, Δ133p53, Δ133p53β, Δ133p53γ, Δ40p53, Δ40p53β, and Δ40p53γ isoforms.28

Results

Expression of p53 isoforms using RT–PCR

By the use of RT–PCR, six different p53 isoforms could be amplified from OLP tissue as well as normal tissue: p53, p53β, p53γ, Δ133p53, Δ133p53β, and Δ133p53γ. All samples were analysed as matched pairs, meaning that one OLP lesion and corresponding matched control were analysed in parallel, though coded, as to hide which sample was lesion and which was control. p53 mRNA could be detected in replicate analyses of all but 1 of the 20 OLP samples as well as all but 1 of the 20 controls. These two samples were positive in one analysis, but negative in the other. The majority of OLP and control samples also expressed the p53β and Δ133p53 isoforms in at least one of the replicate analyses. Expression of p53γ, Δ133p53β and Δ133p53γ was, however, limited to only a few samples. In general the novel p53 isoforms studied were detected in fewer OLP samples compared to matched controls (Fig. 1).

Figure 1
Results from nested RT–PCR analysis of six p53 isoforms. Bars show percentage of positive samples. In total 40 samples were analysed, 20 OLP lesions and 20 sex and aged matched normal tissues. P53 mRNA was detected in all OLP lesions and normal ...

Expression of p63 isoforms

Using quantitative RT–PCR analysis of p63 showed that p63α had highest and ΔNp63 second highest level of all p63 mRNAs. TAp63 had lowest levels in both OLP and corresponding normal tissue. For all isoforms individual variations could be seen (results not shown). Results also showed a general decrease in levels of p63 isoforms in OLP compared to normal tissue. The most pronounced decrease seen in expression of p63γ, p63α and ΔNp63 (P = 0.116; 0.187 and 0.205, respectively). The level of TAp63 was unchanged while a slight reduction in p63β was found in OLP lesions compared to normal tissue. None of these changes were, however, statistically significant (Fig. 2).

Figure 2
Quantitative RT/PCR of the different p63 isoforms in OLP lesions and controls. Black bars represent OLP lesions and white bars normal controls. Results are expressed as mean for all samples analysed in each group and are based on the relative amount of ...

Immunoblot analysis

In order to detect different p53 isoforms also at protein levels, two antibodies were used. DO-1 recognising an epitope located at amino acids 20–25, and therefore not recognising the N-terminal truncated Δ133p53 or Δ40p53 isoforms and DO-12 recognising the p53, p53β, p53γ, Δ133p53, Δ133p53β, Δ133p53γ, Δ40p53, Δ40p53β, and Δ40p53γ isoforms.20 All samples were run in duplicate and results showed detectable levels of p53 protein in only one of the OLP samples. This protein had an identical molecular weight to p53 and bands that might represent p53-isoforms were not detected (data not shown).

Discussion

Increased expression of the p53 tumour suppressor protein has been seen in studies of oral lichen planus, simultaneously with a decreased expression of its sibling p63.10–18 With the discovery of several novel p53 isoforms we therefore wanted to see if this increased expression of p53 protein in fact represented different isoforms which could be important in OLP lesions. By using RT/PCR we could detect three of the isoforms in the majority of OLP and control samples, whereas the remaining three isoforms were detected in only a few samples. In a previous study of p53 isoforms in SCCHN we have shown that the method used,20 nested RT/PCR, is very sensitive and identifies extremely low levels of mRNA. This was clearly shown when comparing RT/PCR results with just one single round of PCR. Using the single round PCR only the p53, p53β and Δ133p53 isoforms were detected.20 These three isoforms were also the ones that could be amplified in the majority of our samples. The inconsistencies seen between replicates of the same samples, using different batches of cDNA, is, as in the study of SCCHN, compatible with low levels of the novel p53 isoform mRNAs. Also, based on the comparatively higher inconsistency in amplification of the p53β and Δ133p53 isoforms seen in this study, we suggest that levels of these isoforms are in fact much lower in OLP lesions compared to tumour- and clinically normal tumour adjacent tissue in patients with SCCHN. This could in turn indicate a more tumour related role for these isoforms. The fact that we in the present study used three times as much RNA for cDNA synthesis, 1 μg of total RNA compared to 300 ng from the tumours, further supports the theory that levels of the novel p53 isoforms really are lower in OLP lesions compared to SCCHN.

By using immunoblotting and antibodies detecting p53/p53β/p53γ and all isoforms analysed respectively, only the p53 protein could be detected in one of the OLP samples, whereas around half of the tumours and a little fewer of the normal tumour adjacent tissue had detectable levels of p53 protein.20 However, none of the novel p53 proteins were expressed at detectable levels in the present or previous study. It should be kept in mind that wild type p53, and maybe also these novel isoforms, is predominantly regulated by post-translational mechanisms, and therefore a direct correlation to RNA levels cannot be expected.29 However, with the reagents available today, none of the novel isoforms could be detected. Other possible explanations could be short half life of the isoforms, in concordance with wild type p53, or tissue specific expression. In the latter case translation of RNA is dependent on tissue specific cofactors and with these absent, RNA is not translated into protein.

For the p53 sibling p63 we could see a down regulation of all isoforms at the RNA level in OLP lesions, though not significant. This is in clear contrast to SCCHN tumours where levels of all isoforms were upregulated compared to clinically normal tumour adjacent tissue. Levels of p63β and ΔNp63 further showed a statistically significant upregulation.26 In OLP lesions levels of the TAp63 isoforms were unchanged compared to the controls (0.0010 versus 0.0011). A discrepancy between RNA and protein levels for the TA isoform specifically has been shown previously, for example in psoriasis lesions.30

As chronic inflammation is known to cause DNA damage, the decreased levels of p63 seen in the chronic inflammatory condition OLP are comparable to changes seen in epithelia after exposure to UV light. In this DNA damaged epithelia decreased ΔNp63 expression is needed for induction of apoptosis.31 This may, as previously suggested, indicate a protective mechanism enabling removal of DNA damaged cells in OLP.18

In conclusion, we have been able to detect RNA of 3 p53 isoforms in the majority of OLP lesions and normal controls analysed. Two of these belong to the group of recently detected novel p53 isoforms. The function of these novel isoforms is, so far, not known but the same isoforms have also been amplified in samples of SCCHN, at seemingly higher levels. This could indicate a more tumour related role for these isoforms. None of them could, however, be detected at protein level with the reagents available today. Therefore, in order to clarify the role of these novel p53 isoforms in OLP lesions, further studies with preferably more isoform specific reagents are needed.

Conflict of interest statement

None declared.

Acknowledgements

We thank Bodil Bäcklund and Inger Cullman for excellent and skilful technical assistance.

This study was supported by grants from The Swedish Cancer Society Grant number 4569-B05-05XAC; Lion’s Cancer Research Foundation, Umeå University; The County Council of Västerbotten and the Swedish Dental Society.

References

1. Axell T., Rundquist L. Oral lichen planus – a demographic study. Community Dent Oral Epidemiol. 1987;15(1):52–56. [PubMed]
2. Dissemond J. Oral lichen planus: an overview. J Dermatol Treat. 2004;15(3):136–140. [PubMed]
3. Sugerman P.B., Savage N.W. Oral lichen planus: causes, diagnosis and management. Aust Dent J. 2002;47(4):290–297. [PubMed]
4. Ebrahimi M., Wahlin Y.B., Coates P.J., Wiik A., Roos G., Nylander K. Detection of antibodies against p63 and p73 isoforms in sera from patients diagnosed with oral lichen planus. J Oral Pathol Med. 2007;36(2):93–98. [PubMed]
5. Epstein J.B., Wan L.S., Gorsky M., Zhang L. Oral lichen planus: progress in understanding its malignant potential and the implications for clinical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96(1):32–37. [PubMed]
6. Pindborg J.J.R.P., Smith C.J., van der Waal I. World Health Organization international histological classification of tumours. 2nd ed. Springer; Berlin: 1997. Histological typing of cancer and precancer of the oral mucosa.
7. Clevers H. At the crossroads of inflammation and cancer. Cell. 2004;118(6):671–674. [PubMed]
8. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. [PMC free article] [PubMed]
9. Philip M., Rowley D.A., Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14(6):433–439. [PubMed]
10. Ogmundsdottir H.M., Hilmarsdottir H., Astvaldsdottir A., Johannsson J.H., Holbrook W.P. Oral lichen planus has a high rate of TP53 mutations. A study of oral mucosa in icelanD. Eur J Oral Sci. 2002;110(3):192–198. [PubMed]
11. Acay R.R., Felizzola C.R., Soares de Araujo N., Machado de Sousa S.O. Evaluation of proliferative potential in oral lichen planus and oral lichenoid lesions using immunohistochemical expression of p53 and Ki67. Oral Oncol. 2005 [PubMed]
12. Chaiyarit P., Ma N., Hiraku Y., Pinlaor S., Yongvanit P., Jintakanon D. Nitrative and oxidative DNA damage in oral lichen planus in relation to human oral carcinogenesis. Cancer Sci. 2005;96(9):553–559. [PubMed]
13. Hirota M., Ito T., Okudela K., Kawabe R., Yazawa T., Hayashi H. Cell proliferation activity and the expression of cell cycle regulatory proteins in oral lichen planus. J Oral Pathol Med. 2002;31(4):204–212. [PubMed]
14. Lee J.J., Kuo M.Y., Cheng S.J., Chiang C.P., Jeng J.H., Chang H.H. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99(4):471–478. [PubMed]
15. Schifter M., Jones A.M., Walker D.M. Epithelial p53 gene expression and mutational analysis, combined with growth fraction assessment, in oral lichen planus. J Oral Pathol Med. 1998;27(7):318–324. [PubMed]
16. Girod S.C., Cesarz D., Fischer U., Krueger G.R. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res. 1995;15(4):1453–1457. [PubMed]
17. Girod S.C., Kramer C., Knufermann R., Krueger G.R. p53 expression in the carcinogenesis in the oral mucosa. J Cell Biochem. 1994;56(4):444–448. [PubMed]
18. Ebrahimi M., Wahlin Y.B., Coates P.J., Sjostrom B., Nylander K. Decreased expression of p63 in oral lichen planus and graft-vs.-host disease associated with oral inflammation. J Oral Pathol Med. 2006;35(1):46–50. [PubMed]
19. Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005;19(18):2122–2137. [PubMed]
20. Boldrup L., Bourdon J., Coates P.J., Sjöström B., Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer. 2007;43(3):617–623. [PMC free article] [PubMed]
21. Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med. 1998;4(7):839–843. [PubMed]
22. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2(3):305–316. [PubMed]
23. Mills A.A., Zheng B., Wang X.J., Vogel H., Roop D.R., Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398(6729):708–713. [PubMed]
24. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398(6729):714–718. [PubMed]
25. Ghioni P., Bolognese F., Duijf P.H., Van Bokhoven H., Mantovani R., Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol. 2002;22(24):8659–8668. [PMC free article] [PubMed]
26. Thurfjell N., Coates P.J., Uusitalo T., Mahani D., Dabelsteen E., Dahlqvist A. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol. 2004;25(1):27–35. [PubMed]
27. Stephen C.W., Helminen P., Lane D.P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol. 1995;248(1):58–78. [PubMed]
28. Vojtesek B., Dolezalova H., Lauerova L., Svitakova M., Havlis P., Kovarik J. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene. 1995;10(2):389–393. [PubMed]
29. Prives C., Hall P.A. The p53 pathway. J Pathol. 1999;187(1):112–126. [PubMed]
30. Gu X., Lundqvist E.N., Coates P.J., Thurfjell N., Wettersand E., Nylander K. Dysregulation of TAp63 mRNA and protein levels in psoriasis. J Invest Dermatol. 2006;126(1):137–141. [PubMed]
31. Hall P.A., McKee P.H., Menage H.D., Dover R., Lane D.P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene. 1993;8(1):203–207. [PubMed]